Источники
praxium*1. Hallett M. Transcranial magnetic stimulation: A primer. Neuron. 2007;55(2):187–199.
2. Rossi S, Antal A, Bestmann S, et al. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology. 2021;132(1):269–306.
3. Lefaucheur J-P, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018). Clinical Neurophysiology. 2020;131(2):474–528.
4. U.S. Food and Drug Administration. K083538 — NeuroStar TMS Therapy System, Model 1.1. 510(k) Premarket Notification; 2008.
5. U.S. Food and Drug Administration. FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive-compulsive disorder. 17 August 2018.
6. BrainsWay Ltd. BrainsWay Receives FDA Clearance for Smoking Addiction in Adults. 24 August 2020.
7. Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression: a randomized non-inferiority trial. The Lancet. 2018;391(10131):1683–1692.
8. Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Canadian Journal of Psychiatry. 2024.
9. Рагимова А. А., Петелин Д. С. и соавт. Применение ТМС в психиатрической и психоневрологической практике: учебно-методическое пособие. М.: Сеченовский Университет; 2022. 171 с.
10. Lisanby SH. Transcranial Magnetic Stimulation: Safety and Risk. National Institute of Mental Health; 2020.